Search
INmune Bio Inc
INMBAdd to Watchlist
2.240USD
-0.060-2.61%
Close 08-31 16:00（ET）
62.08MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-31The current earnings forecast score of INmune Bio Inc is 8.00, ranking 168 out of 378 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 21.00 and a low of 2.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
8.000
Target Price
+243.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
INmune Bio Inc
INMB
4
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is INmune Bio Inc's price target?
Analysts forecast that INmune Bio Inc's price target is USD 7.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 2.00.
How have INmune Bio IncINMB's recent earnings per share performed?
The market expectation was USD -0.05, while INmune Bio IncINMB's earnings per share (EPS) for the previous quarter was USD -0.20. EPS for the next quarter is expected at USD -0.15.
What is the analyst rating for INmune Bio Inc?
Based on the ratings of INmune Bio Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.